Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125241421 | 12524142 | 1 | I | 20160629 | 20160704 | 20160704 | EXP | NG-ROCHE-1787366 | ROCHE | 57.00 | YR | M | Y | 85.00000 | KG | 20160704 | MD | NG | NG |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125241421 | 12524142 | 1 | PS | TARCEVA | ERLOTINIB HYDROCHLORIDE | 1 | Oral | 53728 | 100 | MG | TABLET | QD | |||||||
| 125241421 | 12524142 | 2 | SS | XELODA | CAPECITABINE | 1 | Oral | TWICE DAILY FOR 14 DAYS | 20896 | 1.5 | G | TABLET | BID | ||||||
| 125241421 | 12524142 | 3 | SS | XELODA | CAPECITABINE | 1 | Oral | TWICE DAILY FOR 14 DAYS | 20896 | 1 | G | TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125241421 | 12524142 | 1 | Pancreatic carcinoma metastatic |
| 125241421 | 12524142 | 2 | Pancreatic carcinoma metastatic |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125241421 | 12524142 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125241421 | 12524142 | Death | |
| 125241421 | 12524142 | Palmar-plantar erythrodysaesthesia syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |